Viking Therapeutics clinical trials we track

Check company identity source

Phase 3 4 trials

TrialDrugs studiedStatusPrimary completion
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)NCT07868939VK2735 OralRecruiting2028-10Estimated
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)NCT07868835VK2735Recruiting2028-07Estimated
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383VK2735Active not recruiting2027-07-01Estimated
VK2735 for Weight Management Phase 3NCT07104500VK2735Active not recruiting2027-07-01Estimated

Phase 2 4 trials

TrialDrugs studiedStatusPrimary completion
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055VK2735Completed2025-06-24Actual
VK2735 for Weight Management Phase 2NCT06068946VK2735Completed2024-02-27Actual
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASHNCT04173065Placebos, VK2809Completed2023-05-15Actual
Acute Hip Fracture Study in Patients 65 Years or GreaterNCT02578095VK5211Completed2017-11-15Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily Description: To demonstrate that VK2735 27.5mg, 35mg, and 55mg daily oral (each dose separately) is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks. After: Measure: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily Description: To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks.

Check registry source
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

NCT07868835 · Viking Therapeutics, Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percentage change in body weight for participants receiving VK2735 orally once daily Description: To demonstrate that VK2735 27.5mg, 35mg, and 55mg daily oral (each dose separately) is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks. After: Measure: Percentage change in body weight for participants receiving VK2735 orally once daily Description: To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks.

Check registry source
Acute Hip Fracture Study in Patients 65 Years or Greater

NCT02578095 · Viking Therapeutics, Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Efficacy in hip fracture patients confirmed by DXA scan.. After: Measure: Efficacy in Hip Fracture Patients Confirmed by DXA Scan..

Check registry source